Advertisement
Home »

FLOT Plus Durvalumab Leads to High pCR Rate in Gastric Cancer

Feb 01, 2024

REFERENCES & ADDITIONAL READING

Janjigian YY, et al. Pathological complete response to 5-fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) with or without durvalumab in resectable gastric and gastroesophageal junction cancer: subgroup analysis by region from the phase 3, randomized, double-blind MATTERHORN study. LBA246, ASCO Gastrointestinal Cancers Symposium 2024, January 18-20, 2024, San Francisco, CA, USA.

MORE ARTICLES BELOW

PW Weekly Newsletters

The latest articles and insights from your colleagues in your specialty(ies) of choice.


EXPLORE MORE

Advertisement
Advertisement
ad
ad
MORE ARTICLES BELOW

PW Weekly Newsletters

The latest articles and insights from your colleagues in your specialty(ies) of choice.

SUBSCRIBE NOW

View all newsletters

RELEVANT ARTICLES FOR YOU

Advertisement